Provided by Tiger Trade Technology Pte. Ltd.

BioCardia

1.27
-0.0100-0.78%
Post-market: 1.370.0995+7.83%19:27 EST
Volume:93.17K
Turnover:118.20K
Market Cap:13.48M
PE:-0.77
High:1.38
Open:1.27
Low:1.22
Close:1.28
52wk High:3.20
52wk Low:1.00
Shares:10.61M
Float Shares:4.05M
Volume Ratio:1.53
T/O Rate:2.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6599
EPS(LYR):-2.8960
ROE:-317.47%
ROA:-86.45%
PB:5.13
PE(LYR):-0.44

Loading ...

BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 Cardiamp HF Ii Cell Therapy Pivotal Trial

THOMSON REUTERS
·
Nov 10

BioCardia Enrolls First Patient in Phase 3 CardiAMP HF II Heart Failure Trial

Reuters
·
Nov 10

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

GlobeNewswire
·
Nov 06

BioCardia Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Nov 03

BioCardia Enrolls First Patient in Phase 3 CardiAMP HF II Cell Therapy Trial

Reuters
·
Oct 30

BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 Cardiamp HF Ii Cell Therapy Pivotal Trial

THOMSON REUTERS
·
Oct 30

BioCardia’s Innovative Stem Cell Therapy Trial for Heart Failure: Key Updates and Market Impact

TIPRANKS
·
Oct 28

BioCardia, Inc. - 424B5

THOMSON REUTERS
·
Oct 25

BioCardia Sets Record Date for Annual Meeting

TIPRANKS
·
Oct 08

BioCardia Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire
·
Oct 02

IPS, Inc. Partners with BCDA to Boost Luzon Island’s Digital Infrastructure

TIPRANKS
·
Sep 30

BioCardia Inc. Granted Nasdaq Extension After Falling Below Stockholders’ Equity Listing Requirement

Reuters
·
Sep 24

BioCardia Executives Make Bold Moves with Major Stock Purchases

TIPRANKS
·
Sep 24

Analysts Conflicted on These Healthcare Names: Alector (ALEC), Nurix Therapeutics (NRIX) and BioCardia (BCDA)

TIPRANKS
·
Sep 24

BioCardia Inc. CEO Peter Altman Reports Acquisition of Common Shares

Reuters
·
Sep 24

BioCardia Inc. Raises $5.1 Million Through Sale of Common Stock and Warrants in Recent Offering

Reuters
·
Sep 23

BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 23

BioCardia’s Positive Consultation with Japan’s PMDA

TIPRANKS
·
Sep 22

BioCardia: Completing Responses to Japan's Pmda's Questions & Anticipates Formal Clinical Consultation Near End of Year

THOMSON REUTERS
·
Sep 22

BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure

GlobeNewswire
·
Sep 22